Diabetes and Covid-19

The clinical spectrum of COVID19 is heterogeneous, ranging from mild influenza-like symptoms to acute respiratory distress syndrome, multiple organ failure, and death. Elderly people, diabetes and other comorbidities have been reported as important predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, impaired immune response, and the potential for direct damage to the pancreas by SARSCoV2 may be one of the underlying mechanisms associated with diabetes and COVID19. There is no conclusive evidence to support the discontinuation of angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker, or thiazolidinedione by COVID 19 in diabetic patients. Hypoglycaemic events should be considered when using chloroquine in these individuals

    Related Conference of Diabetes and Covid-19

    October 06-07, 2025

    5th World Congress on Climate Change and Ecosystem

    Madrid, Spain
    October 17-18, 2025

    13th Global Summit and Expo on Pollution Control

    Paris, France
    November 13-14, 2025

    19th World Congress on Biofuels and Bioenergy

    Paris, France
    November 13-14, 2025

    14th World Conference on Earth Science & Geology

    Paris, France
    December 17-18, 2025

    10th Global Summit on Climate Change

    Paris, France
    May 14-15, 2026

    14th World Conference on Climate Change

    London, Aland Islands
    June 22-23, 2026

    8th Global Summit on Environmental Health

    London, UK
    June 29-30, 2026

    13th International Conference on Recycling & Waste Management

    Aix-en-Provence, France
    July 09-10, 2026

    21st World Bioenergy Congress and Expo

    Zurich, Switzerland
    August 10-11, 2026

    14th World Congress and Expo on Green Energy

    Berlin, Germany

    Diabetes and Covid-19 Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in